1

INSTRUCTIONS TO AUTHORS

Clinical report or Case report

Clinical or Case report article (Fewer than 1500 words including summary (no longer than 150 words) text references legend to figures and tables)

A clinical report describes observations of one or severalrare cases whose originality must be demonstrated by adetailed study of the literature. They include the descriptionof the observation(s) reported, followed by a discussion or comments showing the significance of the case(s) and ifrelevant comparing the new observations with cases thathave already been published. The clinical report should modify the current clinical practice by reporting diagnostic dilemma or unusual treatment or complications. Entities that occur coincidentally are not relevant for clinical reports.

  • Must follow the GUIDELINES in (see guidelines Authors OTSR)
  • Your manuscript should be introduced in the following template: (see below).
  • General Guidelines for Clinical Follow-up:
  • A minimum of 5 years of follow-up is mandatory for papers related to total joint arthroplasty with the exception of unexpected complications or failures rates (without minimal follow-up).
  • A minimum of 2 years of follow-up is mandatoryfor papers related to infection(except in case of failure or unusual results).Criteria for infection healing and diagnosis must be clearly defined.
  • A minimum of 1 year of follow-up is mandatoryfor papers reporting traumaand 2 years for papers reporting management of ligament injuries (except in case unexpected rate of failure).
  • A minimum times corresponding to median time for recurrence is recommended for papers reporting tumors.
  • For papers reporting mechanical or biological models (in vitro testing, finite element analysis, mechanical testing) there is no minimal time of follow-up required but reproducibility of the model or criteria of assessment is strongly advised.

Authorship and conflict of interest

We recommend the number or authors to be limited to 6, particularly for case reports. It is important that all authors have a real participation in any part of the study (surgery, laboratory of mechanical experiments, data collection, manuscript edition, statistics). It is corresponding author responsibility to check if all authors have this adequate participation. Whatever the number, all authors must submit a separate filled ICMJE file (to assess conflict of interest see below) that should be enclosed in the electronic submission. Conflict of interest should be declared regarding the submitted paper as well as any conflict outside the paper that may have any relation to the work. Conflict of interest should be detailed for each author at the end of the manuscript.

The journal follows the international practices relative to potential conflicts of interest in the submitted articles. Any manuscript submission must include a conflict of interest disclosure statement. A conflict of interest exists when anauthor and/or co-author has financial or personal relationships with other persons or organizations that may influence professional judgment concerning an essential value (patient’s well-being, research integrity, etc.). The main conflicts of interest are financial interests, clinical trials, occasional consultancies, family relations, etc.All authors of the publication must disclose any financial or personal relationships that could be considered as having apotential conflict of interest only bearing on the subjectmatter of the text published.

1. If there is no conflict of interest in relation with the article submitted, the following statement must be added directly in the manuscript: Conflict of interest: none

2. If there is one (or several) conflict(s) of interest with one or several authors of the article, the complete list of these conflicts of interest must be mentioned at the end of the manuscript, before the bibliographical references and following the presentation below, with the initials of the authors concerned and the name of the company, as in the examples below.

Examples of conflict of interest statements, TO BE ADDED AT THE END OF THE TEXT, under the acknowledgments (if present):

- C. R., E. L. Financial interest in Barbot S.A.;

- E. L. Owner, director, employee, participation in a company’s decision body;

- Other regular activities in Chups SAS;

- J.-J. E. Clinical trials: as principal investigator, coordinator or main researcher for RTM SARL;

- P. L. Clinical trials: as co-investigator, associate researcher collaborator in the study for Light & Co;

- F. W. Occasional consultancies: expert reports for EFS Associated;

- M. D. Occasional consultancies: consultancies for SFC;

- C. G. Conferences: invitations as a presenter for KKS & Son;

- M. S. Conferences: invitations as an auditor (travel expenses paid by a company) for Régis SA;

- C.-A. S. Substantial contributions to the budget of an institution under author’s responsibility, Aphelion;

- M. F. Close relatives employed in the companies declared below;

- A.D. Conflict of interest: none.

3. If no conflict of interest disclosure statement has been included by the author (co-authors), the following statement will be published in the article: Conflict of interest: the authors have not included a conflict of interest disclosure statement.

See editorial Beaufils P. Disclosure of interest or conflict of interest? Orthop Traumatol Surg Res 2012;98(4):367-8. (See OTSR June 2012 Editorial Beaufils)

OTSR agrees to use the “Uniform Requirements for manuscripts submitted to biomedical journals” ( Each author should include in the electronic submission an ICMJE file filed (

Ethical Review Committee Statement

When required (new devices, new treatments) an ethical board review committee statement should be submitted enclosed in the electronic submission.

General additional information

All medications and other drugs should appear under their international nonproprietary name, with the trade name followed by ® in a footnote including the manufacturing laboratory and its head-office. Surgical materials andimplants should be written under their generic name with a footnote mentioning the manufacturer’s name, its headoffice, and the trade name of the device followed by ™. The units of measure for length, height, weight, and volume must be in the metric system or their multiples. Temperatures must be in degrees Celsius and blood pressure in millimeters of mercury. The hematological andbiochemical measurements should be expressed according to the International System of Units. Any abbreviation or acronym is written out in full followed by the abbreviation in parentheses at its first mention in the text. Anatomical descriptions should use the international nomenclature (anatomica parisiensis).

PLEASE REMOVE ALL INSTRUCTIONS PRIOR TO UPLOADING FINAL DRAFT TO EDITORIAL MANAGER

Template for Clinical Report – Orthopaedics Traumatology: Surgery & Research

1

Title page and followings

This page must include the following:

  • Title (containing fewer than 280 characters including spaces)
  • Running title (containing fewer than 80 characters including spaces)
  • Author name(s) (and Christian name) (must follow authorship guidelines at (see guidelines Authors OTSR) and the affiliation
  • The affiliation(s), and full postal address (including ZIP code and country). Please use the vermicular language according to the country of the authors.
  • Identification of the corresponding author with e-mail address.
  • Authors must declare is they had or if their institution had industrial or institutional or academic grants or financial support regarding the current study.

The followings pages must include

  • Ethical review committee statementif mandatory.
  • Word Count (from title to the end of manuscript including tables, legend to figures and references): Maximum is 1500 words for case report.

Template for Clinical Report – Orthopaedics Traumatology: Surgery & Research

1

AbstractYour Abstract must contain fewer than 150 words.

  • The following features should be included in the abstract: What is the current clinical practice or usual evolution of the considered disease. What arguments may justify the publication of this clinical report? Briefly describe the case report regarding underlining the main results. What is the relevant conclusion, according to the literature analysis, to modify the management of the considered disease or the surgery or clinical or biological test?

Level of Evidence: Below Abstract provide a level of Evidence (usually case reports are rated as level IV historical case) (see guidelines Authors OTSR).

Key Words: Three to five key words in English should immediately follow the abstract, chosen among the English key words of the Index Medicus Medical Subject Headings.

1. Introduction (maximum of 200 words)

What is the current clinical practice or usual evolution of the considered disease? What arguments may justify the publication of this clinical report? Does this complication or unusual evolution of the disease was previously published (a minimal literature analysis is mandatory)

2. Case description(maximum of 300 words)

Briefly describe the case report. Describe the history, physical examination, laboratory tests and imaging, treatment, and follow-up of each case.If more than one case are reported please summarize in a table to prevent excessive length of the manuscript. Please focus on major data related to the clinical situation (minimal demographics, minimal function assessment, etc.)

3. Discussion (maximum of 500 words)

Please perform a brief literature review that justify your case report is original and may modify the current clinical practice. Use of table(s) could be recommended to prevent excessive length of discussion section. End the discussion by the clinical relevance (i.e. what is really new, the message to take home)

Template for Clinical Report – Orthopaedics Traumatology: Surgery & Research

1

Acknowledgments

Note any acknowledgments.Begin with, “We thank…” and note the nature of the contribution.

Conflict of interest

Conflict of interest disclosure statement. See above and at (see guidelines Authors OTSR)

References

  • All references cited in the text must be included inthe reference list.All the references in the reference list must be citedin the text by a number between square brackets. If the reference includes more than 6 authors, the six first are cited followed by “et al.”
  • All the references used should be accessible to thereader, which excludes personal communications,unpublished data, doctoral dissertations, andconference papers that have not been published.
  • Thereference list should be presented separately at theend of the article.
  • The reference list should be supplied at the end ofthe manuscript; the references should be listed andnumbered in the order they appear in the text usingArabic numerals.
  • References to Revue de Chirurgie Orthopédiqueshould cite:- before 1 January 2009: the French-language journal (Rev Chir Orthop) with the title in English.- after 1 January 2009: only the English-languagejournal (Orthop Traumatol Surg Res)
  • Journal titles are abbreviated following the U.S.National Library of Medicine nomenclature.Examples of references:
  • Journal article:
  1. Lecerf G, Fessy MH, Philippot R, Massin P, Giraud F, Flecher X, et al. Femoral offset: anatomical concept, definition, assessment, implications for preoperative templating and hip arthroplasty. Orthop Traumatol Surg Res 2009;95:210-9.
  2. Viste A, Chouteau J, Testa R, Chèze L, Fessy MH, Moyen B. Is transverse acetabular ligament an anatomical landmark to reliably orient the cup in primary total hip arthroplasty? Orthop Traumatol Surg Res 2011;97:241-5.
  • Journal supplement:

1. Gleyze P, Clavert P, Flurin PH, Laprelle E, Katz D, Toussaint B, et al. Management of the stiff shoulder. A prospective multicenter comparative study of the six main techniques in use: 235 cases. Orthop Traumatol Surg Res 2011;97(8 Suppl):S167-81.

  • Book:

1. Neyret P, Demey G. Traité de chirurgie du genou. 1st ed. Paris: Elsevier Masson; 2012.

  • Book chapter:

1. Glick JM. Complications of hip arthroscopy by the lateral approach. In: Shermann OH, Minkoff J, editors. Current management of orthopaedics: arthroscopic surgery. Baltimore: W. Wilkins; 1990. p. 1-9.

  • Publication of conference papers:

1. Trojani C. Traumatic acromio- and sternoclavicularcjoint dislocation. In: Huten D, editor. Cahiers d’enseignement de la SoFCOT: conférences d’enseignement. Paris: Elsevier Masson; 2011 [p.21-48].

  • Articles in press are cited as above, followed by: in press, year of publication.
  • In-text citations should appear before commas and periods and located in a sentence immediately after the point they are documenting.

Template for Clinical Report – Orthopaedics Traumatology: Surgery & Research

1

Tables

Tables with table legends and table footnotes at the bottom of the table. Each table should appear on a separate sheet. Tables should be numbered in order of citation in the text. They should be numbered in Arabic numerals in the order they are first cited in the text. (1, 2, 3,...). Any results that can be expressed typographically can be presented in tables,provided that they are clearly presented. For small clinical series, a summary table can display all the data for each ofthe observations. Each table must be cited in the text. Each table should be headed by an informative title and any explanations or notes concerning the units of measure, abbreviations, or statistics should be footnoted below thetable. The tables should not be included in the body of the manuscript.

Legends to figures

  • Figure legends should be on separate pages from the manuscript.
  • The figures are cited in the text by number (Arabic numerals) in the order they appear in the text. They must be separate from the text, i.e., not integrated into the text file. The figures (diagrams, drawings, color or black-and-white photos, videos [for the electronic version], histograms, graphs) should always be provided in separate files, one file for each figure, or in a zipped file with one file per figure. The figures can be supplied in color: they will be published in color in the electronic versions (OTSR and RCOT) and in black and white in the paper version (RCOT).
  • All problems should be addressed to:
  • The figure legends are placed after the text (see above). The figures reinforce the text to illustrate or present theresults that cannot be presented as a table. Figures comprise photographs, radiographs but also histograms and graphs. Figures should be provided in TIFF (.tif), EPS (.eps), or PDF (.pdf) format. Accepted formats for videos are MPG-1 and MPG-2 (.mpg), MPEG-4 (.mp4), AVI (.avi), GIF (.gif), and Quicktime movie (.mov). Word, Powerpoint, and Excel formats should be avoided. To allow the editor to easily identify the figures, please name the files with the figure number and the format used, e.g., “fig1.tif.”
  • The minimum resolution for the figures should be 300 dpi for black-and-white or color photographs and 500-1000 dpi for graphs or diagrams. High resolution is absolutely necessary for printing.
  • For any use of a figure and text already published, the author must provide the written permissions letter. The author must make the request from the publisher and/or author of the original publication.
  • Illustrations with multiple figures (eg, 1A, 1B, 1C) must be labeled "A," "B," and "C" in the lower left hand corner.Each illustration requires a separate legend.
  • Figures should be uploaded and separately labeled in EES.

STROBE Guidelines for authors of OTSR

To be used by authors of all observational clinical studies published in OTSR.For this purpose a cohort study (the term used by STROBE) is considered a longitudinal study typically reporting outcomes of treatment in one or more cohorts; a case-control study is one identifying factors in outcomes; a cross-sectional study is one to identify the prevalence of factors or characteristics in a population at a single point in time.

This checklist table is modified from The STROBE Initiative, and should be filled and submitted within the electronic submission

Item No / Recommendation / Please insert check where included or N/A where not applicable
Title and abstract / 1 / (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction
Background/rationale / 2 / Explain the scientific background and rationale for the investigation being reported
Objectives / 3 / State specific objectives, including any prespecified hypotheses
Methods
Study design / 4 / Present key elements of study design early in the paper
Setting / 5 / Describe the setting, locations, and relevant dates, including periods of recruitment, treatment, follow-up, and data collection
Participants / 6 / (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants
(b)Cohort study—For matched studies, give matching criteria and number of treated and untreated
Case-control study—For matched studies, give matching criteria and the number of controls per case
Variables / 7 / Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement / 8* / For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias / 9 / Describe any efforts to address potential sources of bias
Study size / 10 / Explain how the study size was arrived at
Quantitative variables / 11 / Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods / 12 / (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up was addressed
(e) Describe any sensitivity analyses
Results
Participants / 13* / (a) Report numbers of individuals at each stage of study—eg, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed
(b) Give reasons for nonparticipation at each stage
Descriptive data / 14* / (a) Give characteristics of study participants (eg, demographic, clinical, social) and information on other treatments and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarize follow-up time (eg, average and total amount)
Outcome data / 15* / Report numbers of outcome events or summary measures over time
Main results / 16 / (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses / 17 / Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results / 18 / Summarise key results with reference to study objectives
Limitations / 19 / Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation / 20 / Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability / 21 / Discuss the generalisability (external validity) of the study results
Other information
Funding / 22 / Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls.